Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Common Stock | Options Exercise | $4.91M | +157K | +102.64% | $31.31 | 310K | Feb 27, 2025 | Direct | F1 |
transaction | PFE | Common Stock | Tax liability | -$93.7K | -3.59K | -1.16% | $26.10 | 306K | Feb 27, 2025 | Direct | F2 |
transaction | PFE | Common Stock | Tax liability | -$3.83M | -147K | -47.99% | $26.06 | 159K | Feb 27, 2025 | Direct | F3, F4 |
holding | PFE | Common Stock | 1.95K | Feb 27, 2025 | By Rule 16b-3 Plan |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -157K | -100% | $0.00 | 0 | Feb 27, 2025 | Common Stock | 157K | $31.31 | Direct |
Id | Content |
---|---|
F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
F3 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
F4 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |